McDade Mark's Form 4 filing
Icosavax, Inc.ICVX · filed Aug 2, 2021
- Accession no.
- 0000899243-21-031149
- Filed
- Aug 2, 2021, 9:27 PM ET
- Trade date
- Aug 2, 2021
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market purchases total $3.32M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| McDade MarkCIK 0001242126 | Other: Former 10% Owner |
| Qiming U.S. Healthcare Fund II, L.P.CIK 0001765710 | Other: Former 10% Owner |
| Qiming U.S. Healthcare GP II, LLCCIK 0001868862 | Other: Former 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 2, 2021 | Common Stock | CConversionAcquired | +3,310,228 | $0.00F1 | $0 | 3,310,228 | Direct | |
| Aug 2, 2021 | Common Stock | PPurchaseAcquired | +200,000 | $15.00 | +$3,000,000 | 3,510,228 | Direct | |
| Aug 2, 2021 | Common Stock | PPurchaseAcquired | +8,018 | $15.00 | +$120,270 | 3,518,246 | Direct | |
| Aug 2, 2021 | Common Stock | PPurchaseAcquired | +13,333 | $15.00 | +$199,995 | 3,523,561 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
On August 2, 2021, the shares of Series A-1 Preferred Stock and Series B-1 Preferred Stock converted into shares of the Issuer's common stock at a ratio of 4.1557-for-1 automatically upon the closing of the Issuer's initial public offering without payment or further consideration. The shares have no expiration date. As a result of the Issuer's initial public offering, Qiming U.S. Healthcare Fund II, L.P. ("Qiming") is no longer a 10% owner of the Issuer and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of the Issuer.
Referenced by the price of 1 transaction in Table I and 2 transactions in Table II.